Market Cap
$511.5M
SLN
Silence Therapeutics plc
$10.60 ▼ -1.03%
Prev close $10.71Market cap$511.5M
12-mo target$33.00 (+211.3%)
High Impact Filing (7/10)9 New Institutional Positions3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SLN right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
40 funds
Inst. Value
$76.8M
Inst. Activity
9 buys / 3 sells
Insider Activity
$0.00 buy / $0.00 sell
SEC Reports
5
Price chart 30d -28.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 14, 2026 short_interest_report
Aug 10, 2026 SEC Short Interest: SLN up 32% to 2.4M shares
Settlement 2026-08-14 | Days to cover: 1.00 | ≈5.20% of shares outstanding (est.)
Silence Therapeutics is conducting a $150M underwritten public offering of ADSs, announced concurrently with positive Ph
424B5 — Impact 7/10
Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polycythemia vera (PV). T
8-K — Impact 7/10
Silence Therapeutics reported Q2 2026 net loss of $12.3M ($0.09 per share), narrower than the $27.4M loss in Q2 2025 and
8-K — Impact 5/10
Aug 10, 2026 Insider
Griffiths Richard Ian sold 605,174 shares
10%+ Owner
Aug 10, 2026 Insider
Griffiths Richard Ian sold 100,000 shares
10%+ Owner
Aug 10, 2026 Insider
Griffiths Richard Ian sold 60,000 shares
10%+ Owner
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — ADD
26 shares (—)
Analyst ratings
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 11, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Jun 24, 2026 | Cantor Fitzgerald | INITIATE | Overweight | 49% |
| Jun 17, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Price targets
Where 6 covering analysts think SLN trades over the next 12 months.
$33.00 +211.3% upside Strong Buy
Current$10.60 Low$10.00 Median$29.50 High$75.00 6 analysts
$10.00$75.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 2 neutral · avg impact 5.6/10.
BEARISH424B57/10
Silence Therapeutics is conducting a $150M underwritten public offering of ADSs, announced concurren
Aug 10, 2026
BULLISH8-K7/10
Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polyc
Aug 10, 2026
NEUTRAL8-K5/10
Silence Therapeutics reported Q2 2026 net loss of $12.3M ($0.09 per share), narrower than the $27.4M
Aug 10, 2026
NEUTRAL8-K3/10
Silence Therapeutics filed an updated corporate presentation on June 23, 2026, highlighting pipeline
Jun 24, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 14, 2026
short_interest_report
Short Interest: SLN up 32% to 2.4M shares
Settlement 2026-08-14 | Days to cover: 1.00 | ≈5.20% of shares outstanding (est.)
Jun 3, 2026
Clinical Trial
Study to Assess SLN124 in Patients With Polycythemia Vera
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: SLN124 (Phase 2)
Trial: Study to Assess SLN124 in Patients With Polycythemia Vera Sponsor: Silence Therapeutics plc Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING Cond
Apr 24, 2026
short_interest
FTD: SLN — 78,743 shares ($0.6M) failed to deliver
Settlement: 20260424, Price: $7.84, FTD Value: $617,345.12, SILENCE THERAPEUTICS PLC SPONS
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.09 | $-0.09–$-0.09 | 40.0% | +50.0% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $-0.10 | $-0.10–$-0.10 | 63.0% | +41.2% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-0.36 | $-0.37–$-0.36 | 80.3% | +49.7% | 1↑ 0↓ | $0.0B | 2 |
| Next FY | $-0.38 | $-0.38–$-0.38 | -4.1% | +50.3% | 1↑ 0↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.090 | — |
| 7d ago | $-0.180 | +0.090 |
| 30d ago | $-0.180 | +0.090 |
| 60d ago | $-0.100 | +0.010 |
| 90d ago | $-0.100 | +0.010 |
Institutional ownership
Which big funds own SLN (from quarterly 13F filings) and who is adding or trimming.
40 institutional holders with $76.8M total value (7,025,076 shares) as of 2026-Q2. Top holders: ROYAL, CITADEL, MILLENNIUM. Net buying activity: 9 institutions added/increased vs 3 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 26 | $0.00 | 0.0% | ADD +62.5% |
| CITADEL ADVISORS LLC | 1,329,625 | $14.6M | 19.0% | — |
| MILLENNIUM MANAGEMENT LLC | 909,279 | $10.0M | 13.0% | ADD +62.9% |
| BALYASNY ASSET MANAGEMENT L.P. | 610,980 | $6.7M | 8.7% | — |
| MORGAN STANLEY | 403,172 | $4.4M | 5.8% | DOUBLED +515.7% |
| AMERIPRISE FINANCIAL INC | 370,052 | $4.1M | 5.3% | — |
| JANE STREET GROUP, LLC | 369,151 | $4.1M | 5.3% | DOUBLED +265.8% |
| Caption Management, LLC | 297,900 | $3.3M | 4.3% | — |
| Schonfeld Strategic Advisors LLC | 269,348 | $3.0M | 3.9% | — |
| UBS Group AG | 243,152 | $2.7M | 3.5% | TRIM -32.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | ADD | 16 | 26 | +62.5% | — |
| MORGAN STANLEY | DOUBLED | 65,486 | 403,172 | +515.7% | $4.4M |
| JANE STREET GROUP, LLC | DOUBLED | 100,927 | 369,151 | +265.8% | $4.1M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 115,281 | 184,519 | +60.1% | $2.0M |
| Qube Research & Technologies Ltd | ADD | 104,555 | 163,945 | +56.8% | $1.8M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 52,511 | 155,929 | +196.9% | $1.7M |
| Squarepoint Ops LLC | ADD | 89,469 | 115,918 | +29.6% | $1.3M |
| MARSHALL WACE, LLP | TRIM | 169,616 | 72,039 | -57.5% | $791.0K |
| RAYMOND JAMES FINANCIAL INC | TRIM | 25,000 | 15,000 | -40.0% | $164.7K |
| CITIGROUP INC | DOUBLED | 1,835 | 13,217 | +620.3% | $145.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
1 insiders, 20 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 605,174 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 100,000 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 60,000 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 50,000 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 2,792,826 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 120,000 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 382,000 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 470,820 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 800,000 | — | — |
| Aug 10, 2026 | Griffiths Richard Ian | 10%+ Owner | SELL | 3,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SLN.
Shares short
2,178,055
Settlement Sep 15, 2026
Change vs prior
-10.6%
Semi-monthly cycle
Days to cover
2.5
At avg daily volume
Of shares outstanding
≈4.7%
Estimate — not % of float
All SLN filing & press-release reports (5)
- 424B5 reportAug 10, 2026
- 8-K reportAug 10, 2026
- 8-K reportAug 10, 2026
- 8-K reportJun 24, 2026
- 8-K reportMar 5, 2026